Leuven MindGate member reMYND and Novo Nordisk have entered into a license agreement to further develop reMYND’s ReS39 therapeutic program of diabetes, potentially able to cure the disease.
reMYND’s lead diabetes program ReS39 sustains and increases the insulin production of the pancreas by restoring cell function and insulin signalling in Type 1 and Type 2 diabetes animal models. This convinced Novo Nordisk, a world leader in diabetes treatments, to invest in a treatment for humans.
Koen De Witte, Managing Director of reMYND commented “Even though symptomatic treatments work well, diabetes patients would greatly benefit from restoring durably their endogenous insulin production and/or increasing insulin sensitivity. Novo Nordisk’s agility to step-in once they observed the effects of our ReS39 treatment in their own hands makes the road ahead all the more exciting.”
Under the agreement, reMYND could receive up to 350 million Euros in research and milestone payments, plus royalties on resulting net sales.
reMYND NV, founded in 2002 as a spin-off from the University of Leuven, drives the development of disease-modifying treatments against Alzheimer’s, Parkinson’s, Diabetes, and other orphan protein misfolding disorders.